EP1109582A4 - Technique propre a accentuer et a confiner l'expression de genes - Google Patents
Technique propre a accentuer et a confiner l'expression de genesInfo
- Publication number
- EP1109582A4 EP1109582A4 EP99943819A EP99943819A EP1109582A4 EP 1109582 A4 EP1109582 A4 EP 1109582A4 EP 99943819 A EP99943819 A EP 99943819A EP 99943819 A EP99943819 A EP 99943819A EP 1109582 A4 EP1109582 A4 EP 1109582A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- genes
- enhance
- methods
- confine
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9694798P | 1998-08-18 | 1998-08-18 | |
| US96947P | 1998-08-18 | ||
| PCT/US1999/019095 WO2000010612A1 (fr) | 1998-08-18 | 1999-08-18 | Technique propre a accentuer et a confiner l'expression de genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1109582A1 EP1109582A1 (fr) | 2001-06-27 |
| EP1109582A4 true EP1109582A4 (fr) | 2004-11-03 |
Family
ID=22259886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99943819A Withdrawn EP1109582A4 (fr) | 1998-08-18 | 1999-08-18 | Technique propre a accentuer et a confiner l'expression de genes |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1109582A4 (fr) |
| JP (1) | JP2002523032A (fr) |
| KR (1) | KR20020013463A (fr) |
| CN (1) | CN1321093A (fr) |
| AU (1) | AU763183B2 (fr) |
| CA (1) | CA2340929A1 (fr) |
| IL (1) | IL141473A0 (fr) |
| NZ (1) | NZ509966A (fr) |
| RU (1) | RU2226108C2 (fr) |
| WO (1) | WO2000010612A1 (fr) |
| ZA (1) | ZA200101207B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060105458A1 (en) * | 2002-08-09 | 2006-05-18 | Sidney Cambridge | Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression |
| KR20030019282A (ko) * | 2002-11-27 | 2003-03-06 | 김상태 | βAPP의 C말단 pCT105 원격제어에 의한 치매발병 유도 세포주 개발 |
| CA2600882C (fr) | 2005-03-16 | 2013-02-26 | Metabolix, Inc. | Expression inductible chimiquement de voies biosynthetiques |
| JP2014503173A (ja) * | 2009-11-05 | 2014-02-13 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | 制御された発現系 |
| CN101892256B (zh) * | 2010-01-27 | 2012-05-09 | 中国农业科学院北京畜牧兽医研究所 | 一种培育猪生长激素表达量增强的转基因动物的方法 |
| CA2844283C (fr) | 2011-08-08 | 2024-06-04 | Curelab Oncology, Inc. | Methodes et compositions associees a p62 pour le traitement et la prophylaxie du cancer |
| CN102786599B (zh) * | 2012-08-01 | 2014-01-15 | 中国农业科学院作物科学研究所 | 水稻转录因子Os05g39950基因的应用 |
| SG11201605316VA (en) | 2013-12-29 | 2016-07-28 | Curelab Oncology Inc | Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases |
| CN105925609B (zh) * | 2016-07-14 | 2019-01-08 | 中国医学科学院输血研究所 | 带有标记基因的Tet-on诱导过表达的重组载体及构建方法 |
| CN110016464A (zh) * | 2018-01-08 | 2019-07-16 | 张晋宇 | 用于筛选抗肿瘤物质的系统及方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996027021A1 (fr) * | 1995-03-01 | 1996-09-06 | Cornell Research Foundation, Inc. | Vecteurs d'adenovirus interdependants et leurs procedes d'utilisation |
| WO1998006864A2 (fr) * | 1996-08-15 | 1998-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Regulation spatiale et temporelle de l'expression genique au moyen d'un promoteur proteique du stress associe a une source de chaleur locale |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891718A (en) * | 1996-03-27 | 1999-04-06 | Vical Incorporated | Tetracycline inducible/repressible systems |
-
1999
- 1999-08-18 EP EP99943819A patent/EP1109582A4/fr not_active Withdrawn
- 1999-08-18 AU AU56845/99A patent/AU763183B2/en not_active Ceased
- 1999-08-18 WO PCT/US1999/019095 patent/WO2000010612A1/fr not_active Ceased
- 1999-08-18 JP JP2000565932A patent/JP2002523032A/ja active Pending
- 1999-08-18 KR KR1020017002037A patent/KR20020013463A/ko not_active Ceased
- 1999-08-18 IL IL14147399A patent/IL141473A0/xx unknown
- 1999-08-18 RU RU2001107251/15A patent/RU2226108C2/ru not_active IP Right Cessation
- 1999-08-18 CN CN99811269A patent/CN1321093A/zh active Pending
- 1999-08-18 CA CA002340929A patent/CA2340929A1/fr not_active Abandoned
- 1999-08-18 NZ NZ509966A patent/NZ509966A/en unknown
-
2001
- 2001-02-13 ZA ZA200101207A patent/ZA200101207B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996027021A1 (fr) * | 1995-03-01 | 1996-09-06 | Cornell Research Foundation, Inc. | Vecteurs d'adenovirus interdependants et leurs procedes d'utilisation |
| WO1998006864A2 (fr) * | 1996-08-15 | 1998-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Regulation spatiale et temporelle de l'expression genique au moyen d'un promoteur proteique du stress associe a une source de chaleur locale |
Non-Patent Citations (4)
| Title |
|---|
| HALLAHAN D E ET AL: "SPATIAL AND TEMPORAL CONTROL OF GENE THERAPY USING IONIZING RADIATION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 8, August 1995 (1995-08-01), pages 786 - 791, XP000857200, ISSN: 1078-8956 * |
| MAUCERI H J ET AL: "TUMOR NECROSIS FACTOR ALPHA(TNT-ALPHA) GENE THERAPY TARGETED BY IONIZING RADIATION SELECTIVELY DAMAGES TUMOR VASCULATURE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1996, pages 4311 - 4314, XP002936211, ISSN: 0008-5472 * |
| See also references of WO0010612A1 * |
| WEICHSELBAUM R R ET AL: "GENE THERAPY TARGETED BY RADIATION PREFERENTIALLY RADIOSENSITIZES TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, 15 August 1994 (1994-08-15), pages 4266 - 4269, XP002932030, ISSN: 0008-5472 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020013463A (ko) | 2002-02-20 |
| CA2340929A1 (fr) | 2000-03-02 |
| IL141473A0 (en) | 2002-03-10 |
| WO2000010612A1 (fr) | 2000-03-02 |
| AU5684599A (en) | 2000-03-14 |
| AU763183B2 (en) | 2003-07-17 |
| EP1109582A1 (fr) | 2001-06-27 |
| CN1321093A (zh) | 2001-11-07 |
| RU2226108C2 (ru) | 2004-03-27 |
| NZ509966A (en) | 2003-07-25 |
| ZA200101207B (en) | 2007-01-31 |
| JP2002523032A (ja) | 2002-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL316200A1 (en) | Co-ordinated expression of genes in vivo | |
| IL138191A0 (en) | Expression of trehalose biosynthetic genes in plants | |
| PL340760A1 (en) | Genes of desaturase and their application | |
| HUP0103329A3 (en) | Expression and export of angiostatin and endostatin as immunofusis | |
| HUP0200773A3 (en) | Methods of inducing cacer cell death and tumor regression | |
| IL131486A0 (en) | Gene sequencer and methods | |
| AP2000001762A0 (en) | Method of delivering genes to antigen presenting cells of the skin | |
| AU2001292842A1 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| GB9706381D0 (en) | Improvements relating to the specificity of gene expression | |
| EP1109582A4 (fr) | Technique propre a accentuer et a confiner l'expression de genes | |
| GB9819898D0 (en) | New vaccine and method of use | |
| AU2002245031A1 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| PL352326A1 (en) | Noval vegetable genes and use of same | |
| HUP0204093A3 (en) | Sorghum dwarfing genes and methods of use | |
| AU2584699A (en) | Immediate early genes and methods of use therefor | |
| AU9221098A (en) | Selective expression of genes in plants | |
| AU2002217991A1 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| GB9721075D0 (en) | Materials and methods relating to the stimulation of cells | |
| AU1576501A (en) | Methods to enhance and confine gene expression in cancer therapy | |
| GB9904802D0 (en) | Improvements in or relating to an item of headgear | |
| AU2002241557A1 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| AU2002236579A1 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| SG87764A1 (en) | Methods of layering cache and architectural specific functions to expediate multiple designs | |
| AU6387699A (en) | Rac-like genes and methods of use | |
| EP1210111A4 (fr) | Adn de l'herpesvirus gamma et ses procedes d'utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010224 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20040921 |
|
| 17Q | First examination report despatched |
Effective date: 20050421 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20051103 |